Role of the collagen receptor LAIR-1 in glioma progression and the tumor immune microenvironment
胶原蛋白受体LAIR-1在神经胶质瘤进展和肿瘤免疫微环境中的作用
基本信息
- 批准号:10462939
- 负责人:
- 金额:$ 39.73万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-03-01 至 2027-02-28
- 项目状态:未结题
- 来源:
- 关键词:AffectAffinityB-LymphocytesBehaviorBindingBiochemicalBone MarrowBrain NeoplasmsCD8-Positive T-LymphocytesCell-Mediated CytolysisCellsCollagenCollagen ReceptorsComplexDDR1 geneDDR2 geneDiffuseDown-RegulationExcisionExtracellular MatrixGenetically Engineered MouseGlioblastomaGliomaGlycoproteinsGoalsHumanITIMImmuneImmune responseImmunityImmunoglobulin DomainImmunoglobulinsIn VitroInfiltrationIntegrinsLeucocytic infiltrateLeukocytesMalignant - descriptorMalignant NeoplasmsMalignant neoplasm of cervix uteriMediatingMicrogliaModelingNatural Killer CellsOperative Surgical ProceduresOutcomePathogenesisPathologicPatientsPhenotypePlayPrimary Brain NeoplasmsRadiation therapyReceptor Protein-Tyrosine KinasesRecurrenceRenal carcinomaRoleSignal PathwaySignal TransductionSolid NeoplasmT-LymphocyteTestingTherapeuticTherapeutic EffectTissuesTranslationsTreatment EfficacyTumor Cell InvasionTumor ImmunityTumor-infiltrating immune cellsangiogenesisanti-tumor immune responsebrain tissuecancer cellchemotherapycytotoxiccytotoxicitydiscoidin receptorextracellularimmune activationin vivoknock-downleukocyte activationmacrophagemalignant breast neoplasmmigrationmonocyteneoplastic cellneuropathologynew therapeutic targetreceptorresponsestandard of caretumortumor behaviortumor growthtumor microenvironmenttumor progressiontumor-immune system interactions
项目摘要
ABSTRACT
High-grade gliomas (HGG) are the deadliest of all primary brain tumors. They are incurable and median survival
is between 18-24 months. Gliomas infiltrate the healthy brain tissue surrounding the tumor. Thus, even if these
tumors do not metastasize, patients die due to local tumor recurrence. Collagens are a central component of the
extracellular matrix of high-grade gliomas, and promote invasion and tumor growth. How they do so is complex,
and not fully understood. Collagen provides structural stiffness to the extracellular matrix, through physical
mechanisms. In addition to physical mechanisms, biochemically collagen affects intracellular mechanisms.
Collagen affects intracellular signaling by interacting with a large number of collagen receptors. These receptors
are: integrins, discoidin domain receptors DDR1 and DDR2, GPVI, MRC2 and LAIR-1. Leukocyte-associated
immunoglobulin-like receptor-1 (LAIR- 1) is a transmembrane glycoprotein, its extracellular segment contains a
single immunoglobulin-like (Ig- like) domain, and its intracellular segment has two immuno- receptor tyrosine-
based inhibitory motifs (ITIMs). LAIR-1 is strongly expressed on T cells, B cells, natural killer (NK) cells,
macrophages and other immune cells. LAIR-1 strongly suppresses immune cell activation, thus reducing
immune responses. Collagen-rich tumors, especially collagens I and III activate LAIR-1 in CD8+ T cells, and
reduce T cell-mediated cytotoxicity. Thus, activation of LAIR-1 on immune cells has been proposed as a
mechanism by which tumors inhibit antitumor immune responses. Surprisingly, we found that LAIR-1 is also
expressed in glioma cells. Expression of LAIR-1 in other solid tumors, such as cervical, breast and kidney cancer
increases tumor aggressiveness. Thus, we postulate that LAIR-1 could affect glioma progression by directly
increasing the pathogenesis of cancer cells, and indirectly, by inhibiting the anti-tumor cytotoxic immune
responses. Knockdown of collagen from genetically engineered mouse models of glioma increased median
survival, and reduced LAIR-1 expression within brain tumors. Thus, collagen could directly inhibit anti-glioma
immune responses, or affect the malignant behavior of glioma cells. There is thus a critical need for a mechanistic
understanding of how LAIR-1 expressed by either infiltrating immune cells or glioma tumor cells contributes to
glioma progression and invasion and how it remodels the tumor immune microenvironment. Our long-term goal
is to understand how the extracellular tumor matrix, through its expression of collagen affects tumor progression
and anti-tumor immunity. Our overall objectives in this application are to test the hypothesis that LAIR-1
expression in glioma cells increases tumor progression (AIM 1), the role of LAIR-1 expression in regulating the
function of infiltrating immune cells (AIM 2), and determine the therapeutic potential of the inhibition of LAIR-1 in
glioma models (AIM 3). Our central hypothesis is that LAIR-1 plays essential pathological roles that contribute
to glioma progression through its expression in glioma cells and in immune cells and that inhibiting LAIR-1
signaling could uncover novel therapeutic targets for HGG.
摘要
高级别胶质瘤(HGG)是所有原发脑肿瘤中最致命的。他们是不治之症,中位存活率
在18-24个月之间。胶质瘤渗入肿瘤周围的健康脑组织。因此,即使这些
肿瘤不转移,患者死于局部肿瘤复发。胶原蛋白是心脏的核心成分
高级别胶质瘤的细胞外基质,促进肿瘤的侵袭和生长。他们如何做到这一点是复杂的,
而且还没有完全被理解。胶原蛋白通过物理作用为细胞外基质提供结构硬度
机制。除了物理机制外,生物化学上的胶原蛋白还影响细胞内机制。
胶原蛋白通过与大量的胶原蛋白受体相互作用而影响细胞内信号转导。这些受体
它们是:整合素、盘状结构域受体DDR1和DDR2、GPVI、MRC2和LAIR-1。白细胞相关
免疫球蛋白样受体-1(LAIR-1)是一种跨膜糖蛋白,其胞外段含有一个
单个免疫球蛋白样(Ig样)结构域,其胞内片段具有两个免疫受体酪氨酸-
基于抑制基序(ITIMs)。LAIR-1在T细胞、B细胞、自然杀伤(NK)细胞、
巨噬细胞和其他免疫细胞。LAIR-1强烈抑制免疫细胞激活,从而减少
免疫反应。富含胶原的肿瘤,特别是I型和III型胶原,激活CD8+T细胞中的LAIR-1,以及
降低T细胞介导的细胞毒作用。因此,LAIR-1对免疫细胞的激活被认为是一种
肿瘤抑制抗肿瘤免疫反应的机制。令人惊讶的是,我们发现LAIR-1也是
在胶质瘤细胞中表达。LAIR-1在宫颈癌、乳腺癌、肾癌等实体瘤中的表达
增加肿瘤的侵袭性。因此,我们推测LAIR-1可能通过直接影响神经胶质瘤的进展。
增强肿瘤细胞的致病作用,并间接通过抑制抗肿瘤的细胞毒免疫
回应。基因工程小鼠胶质瘤模型胶原基因敲除后中位数增加
存活,并减少脑肿瘤内LAIR-1的表达。因此,胶原蛋白可以直接抑制胶质瘤的生长。
免疫反应,或影响胶质瘤细胞的恶性行为。因此,迫切需要一种机械式的
了解浸润性免疫细胞或胶质瘤细胞表达LAIR-1是如何促进
胶质瘤的进展和侵袭,以及它如何重塑肿瘤免疫微环境。我们的长期目标
是了解细胞外肿瘤基质是如何通过其胶原蛋白的表达影响肿瘤进展的
和抗肿瘤免疫。我们在这个应用程序中的总体目标是测试LAIR-1的假设
在胶质瘤细胞中的表达促进肿瘤进展(AIM-1),LAIR-1的表达在调节
浸润性免疫细胞(AIM-2)的功能,并确定抑制LAIR-1的治疗潜力
脑胶质瘤模型(AIM 3)。我们的中心假设是LAIR-1起着重要的病理作用
通过在胶质瘤细胞和免疫细胞中的表达及抑制LAIR-1而促进胶质瘤的进展
信号转导可以发现治疗HGG的新靶点。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Pedro R Lowenstein其他文献
Combined cytotoxic and immune-stimulatory gene therapy for primary adult high-grade glioma: a phase 1, first-in-human trial
原发性成人高级别胶质瘤的联合细胞毒性和免疫刺激基因治疗:一项 1 期、首次人体试验
- DOI:
10.1016/s1470-2045(23)00347-9 - 发表时间:
2023-09-01 - 期刊:
- 影响因子:35.900
- 作者:
Yoshie Umemura;Daniel Orringer;Larry Junck;Maria L Varela;Molly E J West;Syed M Faisal;Andrea Comba;Jason Heth;Oren Sagher;Denise Leung;Aaron Mammoser;Shawn Hervey-Jumper;Daniel Zamler;Viveka N Yadav;Patrick Dunn;Wajd Al-Holou;Todd Hollon;Michelle M Kim;Daniel R Wahl;Sandra Camelo-Piragua;Pedro R Lowenstein - 通讯作者:
Pedro R Lowenstein
Crossing the Rubicon
破釜沉舟
- DOI:
10.1038/nbt0109-42 - 发表时间:
2009-01-01 - 期刊:
- 影响因子:41.700
- 作者:
Pedro R Lowenstein - 通讯作者:
Pedro R Lowenstein
Pedro R Lowenstein的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Pedro R Lowenstein', 18)}}的其他基金
Role of the collagen receptor LAIR-1 in glioma progression and the tumor immune microenvironment
胶原蛋白受体LAIR-1在神经胶质瘤进展和肿瘤免疫微环境中的作用
- 批准号:
10581659 - 财政年份:2022
- 资助金额:
$ 39.73万 - 项目类别:
The role of collagen and its signaling mechanisms in glioma progression and invasion.
胶原蛋白及其信号传导机制在神经胶质瘤进展和侵袭中的作用。
- 批准号:
10539332 - 财政年份:2021
- 资助金额:
$ 39.73万 - 项目类别:
The role of collagen and its signaling mechanisms in glioma progression and invasion.
胶原蛋白及其信号传导机制在神经胶质瘤进展和侵袭中的作用。
- 批准号:
10387976 - 财政年份:2021
- 资助金额:
$ 39.73万 - 项目类别:
Neuroimmunology of Malignant Brain Tumors: Innate Mechanisms
恶性脑肿瘤的神经免疫学:先天机制
- 批准号:
9215708 - 财政年份:2016
- 资助金额:
$ 39.73万 - 项目类别:
Neuroimmunology of Malignant Brain Tumors: Innate Mechanisms
恶性脑肿瘤的神经免疫学:先天机制
- 批准号:
9115388 - 财政年份:2016
- 资助金额:
$ 39.73万 - 项目类别:
Mechanisms of glioma growth and invasion novel therapeutic strategies
神经胶质瘤生长和侵袭的机制新的治疗策略
- 批准号:
8883736 - 财政年份:2013
- 资助金额:
$ 39.73万 - 项目类别:
Mechanisms of glioma growth and invasion novel therapeutic strategies
神经胶质瘤生长和侵袭的机制新的治疗策略
- 批准号:
9039671 - 财政年份:2013
- 资助金额:
$ 39.73万 - 项目类别:
Mechanisms of glioma growth and invasion novel therapeutic strategies
神经胶质瘤生长和侵袭的机制新的治疗策略
- 批准号:
9250229 - 财政年份:2013
- 资助金额:
$ 39.73万 - 项目类别:
Mechanisms of glioma growth and invasion novel therapeutic strategies
神经胶质瘤生长和侵袭的机制新的治疗策略
- 批准号:
8606906 - 财政年份:2013
- 资助金额:
$ 39.73万 - 项目类别:
Mechanisms of glioma growth and invasion novel therapeutic strategies
神经胶质瘤生长和侵袭的机制新的治疗策略
- 批准号:
8480082 - 财政年份:2013
- 资助金额:
$ 39.73万 - 项目类别:
相似海外基金
Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
- 批准号:
23H01982 - 财政年份:2023
- 资助金额:
$ 39.73万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
- 批准号:
23KJ0116 - 财政年份:2023
- 资助金额:
$ 39.73万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
- 批准号:
10598276 - 财政年份:2023
- 资助金额:
$ 39.73万 - 项目类别:
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
- 批准号:
10682794 - 财政年份:2023
- 资助金额:
$ 39.73万 - 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233343 - 财政年份:2023
- 资助金额:
$ 39.73万 - 项目类别:
Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233342 - 财政年份:2023
- 资助金额:
$ 39.73万 - 项目类别:
Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
- 批准号:
479363 - 财政年份:2023
- 资助金额:
$ 39.73万 - 项目类别:
Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
- 批准号:
10681989 - 财政年份:2023
- 资助金额:
$ 39.73万 - 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
- 批准号:
2237240 - 财政年份:2023
- 资助金额:
$ 39.73万 - 项目类别:
Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
- 批准号:
2305592 - 财政年份:2023
- 资助金额:
$ 39.73万 - 项目类别:
Continuing Grant